PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33504904-0	2021	Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients.	osimertinib	90-101	IL2 inducible T cell kinase	Homo sapiens	69-72	
34599981-6	2022	A PAR2 inhibitor facilitated osimertinib to attenuate EGFR transactivation, ERK phosphorylation, EMT and PD-L1 expression which were associated to osimertinib resistance.	osimertinib	29-40	IL2 inducible T cell kinase	Homo sapiens	97-100	
34599981-6	2022	A PAR2 inhibitor facilitated osimertinib to attenuate EGFR transactivation, ERK phosphorylation, EMT and PD-L1 expression which were associated to osimertinib resistance.	osimertinib	147-158	IL2 inducible T cell kinase	Homo sapiens	97-100	
34599981-8	2022	Importantly, this reversal effect of PAR2 blockade was uncovered to depend on ERK-mediated EMT and PD-L1, since inhibition of beta-arrestin or ERK, which could be modulated by PAR2, sensitized osimertinib to prevent EMT, PD-L1 expression and consequently overcame osimertinib resistance.	osimertinib	193-204	IL2 inducible T cell kinase	Homo sapiens	91-94	
34599981-8	2022	Importantly, this reversal effect of PAR2 blockade was uncovered to depend on ERK-mediated EMT and PD-L1, since inhibition of beta-arrestin or ERK, which could be modulated by PAR2, sensitized osimertinib to prevent EMT, PD-L1 expression and consequently overcame osimertinib resistance.	osimertinib	193-204	IL2 inducible T cell kinase	Homo sapiens	216-219	
34599981-0	2022	PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression.	osimertinib	23-34	IL2 inducible T cell kinase	Homo sapiens	111-114